Glenmark Pharmaceuticals has informed that it attached media release today tilted ‘Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities’.
The above information is a part of company’s filings submitted to BSE.